The world has woken up to a new era, with Donald Trump elected as US president – a huge victory for a political outsider and the 'silent majority' who felt sidelined by the status quo.

2025 will be a challenging year for many sectors with multiple headwinds, and the pharmaceutical industry is no exception. The industry is grappling with significant market shifts amidst emerging ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines – including debunked claims that they can cause autism – but refused to ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery.

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients ...